{
    "abstract": "Treating tuberculosis (TB) requires a multidrug course of treatment lasting 6 months, or longer for drug-resistant TB, which is difficult to complete and often not well tolerated. Treatment failure and recurrence after end-of-treatment can have devastating consequences, including progressive debilitation, death, the transmission of Mycobacterium tuberculosis \u2013 the infectious agent responsible for causing TB \u2013 to others, and may be associated with the development of drug-resistant TB. The burden on health systems is important, with severe economic consequences. Vaccines have the potential to serve as immunotherapeutic adjuncts to antibiotic treatment regimens for TB. A therapeutic vaccine for TB patients, administered towards completion of a prescribed course of drug therapy or at certain time(s) during treatment, could improve outcomes through immune-mediated control and even clearance of bacteria, potentially prevent re-infection, and provide an opportunity to shorten and simplify drug treatment regimens. The preferred product characteristics (PPC) for therapeutic TB vaccines described in this document are intended to provide guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. This document presents potential clinical end-points for evidence generation and discusses key considerations about potential clinical development strategies.",
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Alimuddin",
                    "initial": "A.",
                    "last": "Zumla"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Raviglione"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Hafner"
                },
                {
                    "first": "C. Fordham",
                    "initial": "C.F.",
                    "last": "Von Reyn"
                }
            ],
            "doi": "10.1056/NEJMra1200894",
            "firstpage": "745",
            "issn": "00284793",
            "lastpage": "755",
            "pub_year": 2013,
            "title": "Tuberculosis",
            "volume": "368"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Edine W.",
                    "initial": "E.W.",
                    "last": "Tiemersma"
                },
                {
                    "first": "Marieke J.",
                    "initial": "M.J.",
                    "last": "van der Werf"
                },
                {
                    "first": "Martien W.",
                    "initial": "M.W.",
                    "last": "Borgdorff"
                },
                {
                    "first": "Brian G.",
                    "initial": "B.G.",
                    "last": "Williams"
                },
                {
                    "first": "Nico J.D.",
                    "initial": "N.J.D.",
                    "last": "Nagelkerke"
                }
            ],
            "doi": "10.1371/journal.pone.0017601",
            "issn": "19326203",
            "pmid": "21483732",
            "pub_year": 2011,
            "title": "Natural history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review",
            "volume": "6"
        },
        "b0025": {
            "authors": [
                {
                    "first": "John F.",
                    "initial": "J.F.",
                    "last": "Murray"
                },
                {
                    "first": "Dean E.",
                    "initial": "D.E.",
                    "last": "Schraufnagel"
                },
                {
                    "first": "Philip C.",
                    "initial": "P.C.",
                    "last": "Hopewell"
                }
            ],
            "doi": "10.1513/AnnalsATS.201509-632PS",
            "firstpage": "1749",
            "issn": "23256621",
            "lastpage": "1759",
            "pmid": "26653188",
            "pub_year": 2015,
            "title": "Treatment of tuberculosis: A historical perspective",
            "volume": "12"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Shruthi",
                    "initial": "S.",
                    "last": "Ravimohan"
                },
                {
                    "first": "Hardy",
                    "initial": "H.",
                    "last": "Kornfeld"
                },
                {
                    "first": "Drew",
                    "initial": "D.",
                    "last": "Weissman"
                },
                {
                    "first": "Gregory P.",
                    "initial": "G.P.",
                    "last": "Bisson"
                }
            ],
            "doi": "10.1183/16000617.0077-2017",
            "issn": "09059180",
            "pmid": "29491034",
            "pub_year": 2018,
            "title": "Tuberculosis and lung damage: From epidemiology to pathophysiology",
            "volume": "27"
        },
        "b0035": null,
        "b0040": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Diel"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Nienhaus"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Lampenius"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "R\u00fcsch-Gerdes"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Richter"
                }
            ],
            "doi": "10.1016/j.rmed.2014.09.021",
            "firstpage": "1677",
            "issn": "09546111",
            "lastpage": "1687",
            "pmid": "25443398",
            "pub_year": 2014,
            "title": "Cost of multi drug resistance tuberculosis in Germany",
            "volume": "108"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Henry M.",
                    "initial": "H.M.",
                    "last": "Blumberg"
                },
                {
                    "first": "William J.",
                    "initial": "W.J.",
                    "last": "Burman"
                },
                {
                    "first": "Richard E.",
                    "initial": "R.E.",
                    "last": "Chaisson"
                },
                {
                    "first": "Charles L.",
                    "initial": "C.L.",
                    "last": "Daley"
                },
                {
                    "first": "Sue C.",
                    "initial": "S.C.",
                    "last": "Etkind"
                },
                {
                    "first": "Lloyd N.",
                    "initial": "L.N.",
                    "last": "Friedman"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Fujiwara"
                },
                {
                    "first": "Malgosia",
                    "initial": "M.",
                    "last": "Grzemska"
                },
                {
                    "first": "Philip C.",
                    "initial": "P.C.",
                    "last": "Hopewell"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Iseman"
                },
                {
                    "first": "Robert M.",
                    "initial": "R.M.",
                    "last": "Jasmer"
                },
                {
                    "first": "Venkatarama",
                    "initial": "V.",
                    "last": "Koppaka"
                },
                {
                    "first": "Richard I.",
                    "initial": "R.I.",
                    "last": "Menzies"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "O'Brien"
                },
                {
                    "first": "Randall R.",
                    "initial": "R.R.",
                    "last": "Reves"
                },
                {
                    "first": "Lee B.",
                    "initial": "L.B.",
                    "last": "Reichman"
                },
                {
                    "first": "Patricia M.",
                    "initial": "P.M.",
                    "last": "Simone"
                },
                {
                    "first": "Jeffrey R.",
                    "initial": "J.R.",
                    "last": "Starke"
                },
                {
                    "first": "Andrew A.",
                    "initial": "A.A.",
                    "last": "Vernon"
                }
            ],
            "doi": "10.1164/rccm.167.4.603",
            "firstpage": "603",
            "issn": "1073449X",
            "lastpage": "662",
            "pmid": "12588714",
            "pub_year": 2003,
            "title": "American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.",
            "volume": "167"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Verver"
                },
                {
                    "first": "Robin M.",
                    "initial": "R.M.",
                    "last": "Warren"
                },
                {
                    "first": "Nulda",
                    "initial": "N.",
                    "last": "Beyers"
                },
                {
                    "first": "Madalene",
                    "initial": "M.",
                    "last": "Richardson"
                },
                {
                    "first": "Gian D.",
                    "initial": "G.D.",
                    "last": "Van Der Spuy"
                },
                {
                    "first": "Martien W.",
                    "initial": "M.W.",
                    "last": "Borgdorff"
                },
                {
                    "first": "Donald A.",
                    "initial": "D.A.",
                    "last": "Enarson"
                },
                {
                    "first": "Marcel A.",
                    "initial": "M.A.",
                    "last": "Behr"
                },
                {
                    "first": "Paul D.",
                    "initial": "P.D.",
                    "last": "Van Helden"
                }
            ],
            "doi": "10.1164/rccm.200409-1200OC",
            "firstpage": "1430",
            "issn": "1073449X",
            "lastpage": "1435",
            "pmid": "15831840",
            "pub_year": 2005,
            "title": "Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis",
            "volume": "171"
        },
        "b0055": {
            "authors": [
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Nunn"
                },
                {
                    "first": "Patrick P.J.",
                    "initial": "P.P.J.",
                    "last": "Phillips"
                },
                {
                    "first": "D. A.",
                    "initial": "D.A.",
                    "last": "Mitchison"
                }
            ],
            "firstpage": "241",
            "issn": "10273719",
            "lastpage": "242",
            "pmid": "20074418",
            "pub_year": 2010,
            "title": "Timing of relapse in short-course chemotherapy trials for tuberculosis",
            "volume": "14"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Marjorie Z.",
                    "initial": "M.Z.",
                    "last": "Imperial"
                },
                {
                    "first": "Payam",
                    "initial": "P.",
                    "last": "Nahid"
                },
                {
                    "first": "Patrick P.J.",
                    "initial": "P.P.J.",
                    "last": "Phillips"
                },
                {
                    "first": "Geraint R.",
                    "initial": "G.R.",
                    "last": "Davies"
                },
                {
                    "first": "Katherine",
                    "initial": "K.",
                    "last": "Fielding"
                },
                {
                    "first": "Debra",
                    "initial": "D.",
                    "last": "Hanna"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Hermann"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Wallis"
                },
                {
                    "first": "John L.",
                    "initial": "J.L.",
                    "last": "Johnson"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Lienhardt"
                },
                {
                    "first": "Rada M.",
                    "initial": "R.M.",
                    "last": "Savic"
                }
            ],
            "doi": "10.1038/s41591-018-0224-2",
            "firstpage": "1708",
            "issn": "10788956",
            "lastpage": "1715",
            "pmid": "30397355",
            "pub_year": 2018,
            "title": "A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis",
            "volume": "24"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Hyungmin",
                    "initial": "H.",
                    "last": "Lee"
                },
                {
                    "first": "Jusang",
                    "initial": "J.",
                    "last": "Kim"
                }
            ],
            "doi": "10.1016/j.phrp.2014.11.001",
            "firstpage": "S8",
            "issn": "22109099",
            "lastpage": "S17",
            "pub_year": 2014,
            "title": "A Study on the Relapse Rate of Tuberculosis and Related Factors in Korea Using Nationwide Tuberculosis Notification Data",
            "volume": "5"
        },
        "b0070": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Thomas"
                },
                {
                    "first": "P. G.",
                    "initial": "P.G.",
                    "last": "Gopi"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Santha"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Chandrasekaran"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Subramani"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Selvakumar"
                },
                {
                    "first": "S. I.",
                    "initial": "S.I.",
                    "last": "Eusuff"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Sadacharam"
                },
                {
                    "first": "P. R.",
                    "initial": "P.R.",
                    "last": "Narayanan"
                }
            ],
            "firstpage": "556",
            "issn": "10273719",
            "lastpage": "561",
            "pmid": "15875929",
            "pub_year": 2005,
            "title": "Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India",
            "volume": "9"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Andreas H.",
                    "initial": "A.H.",
                    "last": "Diacon"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Pym"
                },
                {
                    "first": "Martin P.",
                    "initial": "M.P.",
                    "last": "Grobusch"
                },
                {
                    "first": "Jorge M.",
                    "initial": "J.M.",
                    "last": "De Los Rios"
                },
                {
                    "first": "Eduardo",
                    "initial": "E.",
                    "last": "Gotuzzo"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Vasilyeva"
                },
                {
                    "first": "Vaira",
                    "initial": "V.",
                    "last": "Leimane"
                },
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "Andries"
                },
                {
                    "first": "Nyasha",
                    "initial": "N.",
                    "last": "Bakare"
                },
                {
                    "first": "Tine",
                    "initial": "T.",
                    "last": "De Marez"
                },
                {
                    "first": "Myriam",
                    "initial": "M.",
                    "last": "Haxaire-Theeuwes"
                },
                {
                    "first": "Nacer",
                    "initial": "N.",
                    "last": "Lounis"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Meyvisch"
                },
                {
                    "first": "Els",
                    "initial": "E.",
                    "last": "De Paepe"
                },
                {
                    "first": "Rolf P.G.",
                    "initial": "R.P.G.",
                    "last": "Van Heeswijk"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Dannemann"
                }
            ],
            "doi": "10.1056/NEJMoa1313865",
            "firstpage": "723",
            "issn": "00284793",
            "lastpage": "732",
            "pmid": "25140958",
            "pub_year": 2014,
            "title": "Multidrug-resistant tuberculosis and culture conversion with bedaquiline",
            "volume": "371"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Alexander S.",
                    "initial": "A.S.",
                    "last": "Pym"
                },
                {
                    "first": "Andreas H.",
                    "initial": "A.H.",
                    "last": "Diacon"
                },
                {
                    "first": "Shen Jie",
                    "initial": "S.J.",
                    "last": "Tang"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Conradie"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Danilovits"
                },
                {
                    "first": "Charoen",
                    "initial": "C.",
                    "last": "Chuchottaworn"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Vasilyeva"
                },
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "Andries"
                },
                {
                    "first": "Nyasha",
                    "initial": "N.",
                    "last": "Bakare"
                },
                {
                    "first": "Tine",
                    "initial": "T.",
                    "last": "De Marez"
                },
                {
                    "first": "Myriam",
                    "initial": "M.",
                    "last": "Haxaire-Theeuwes"
                },
                {
                    "first": "Nacer",
                    "initial": "N.",
                    "last": "Lounis"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Meyvisch"
                },
                {
                    "first": "Ben",
                    "initial": "B.",
                    "last": "Van Baelen"
                },
                {
                    "first": "Rolf P.G.",
                    "initial": "R.P.G.",
                    "last": "Van Heeswijk"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Dannemann"
                },
                {
                    "first": "Xiaohong",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Naihui",
                    "initial": "N.",
                    "last": "Chu"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "De Los Rios"
                },
                {
                    "first": "Dina",
                    "initial": "D.",
                    "last": "Diaz"
                },
                {
                    "first": "Vladislav",
                    "initial": "V.",
                    "last": "Erokhin"
                },
                {
                    "first": "Victor",
                    "initial": "V.",
                    "last": "Flores"
                },
                {
                    "first": "Sung Chul",
                    "initial": "S.C.",
                    "last": "Hwang"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Iberico"
                },
                {
                    "first": "Boris",
                    "initial": "B.",
                    "last": "Kazennyi"
                },
                {
                    "first": "Young Sam",
                    "initial": "Y.S.",
                    "last": "Kim"
                },
                {
                    "first": "Anu",
                    "initial": "A.",
                    "last": "Kurve"
                },
                {
                    "first": "Mykhaylo",
                    "initial": "M.",
                    "last": "Kuzhko"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Jung Kwon"
                },
                {
                    "first": "Vaira",
                    "initial": "V.",
                    "last": "Leimane"
                },
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Lyepshina"
                },
                {
                    "first": "Andrey",
                    "initial": "A.",
                    "last": "Maryandyshev"
                },
                {
                    "first": "Vasiliy",
                    "initial": "V.",
                    "last": "Melnyk"
                },
                {
                    "first": "Ronelle",
                    "initial": "R.",
                    "last": "Narasimooloo"
                },
                {
                    "first": "Lihua",
                    "initial": "L.",
                    "last": "Qiu"
                },
                {
                    "first": "G\u00f6nen\u00e7",
                    "initial": "G.",
                    "last": "Ortak\u00f6yl\u00fc"
                },
                {
                    "first": "Seref",
                    "initial": "S.",
                    "last": "Ozkara"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Reano"
                },
                {
                    "first": "Tae Sun",
                    "initial": "T.S.",
                    "last": "Shim"
                },
                {
                    "first": "Eduardo Ticona",
                    "initial": "E.T.",
                    "last": "Chavez"
                },
                {
                    "first": "Tawatchai",
                    "initial": "T.",
                    "last": "Wiwatworapan"
                },
                {
                    "first": "Xia",
                    "initial": "X.",
                    "last": "Zhang"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1183/13993003.00724-2015",
            "firstpage": "564",
            "issn": "09031936",
            "lastpage": "574",
            "pmid": "26647431",
            "pub_year": 2016,
            "title": "Bedaquiline in the treatment of multidrug- and extensively drugresistant tuberculosis",
            "volume": "47"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Riya",
                    "initial": "R.",
                    "last": "Moodley"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Godec"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1183/16000617.0080-2015",
            "firstpage": "29",
            "issn": "16000617",
            "lastpage": "35",
            "pmid": "26929418",
            "pub_year": 2016,
            "title": "Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials",
            "volume": "25"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Thi Van Anh",
                    "initial": "T.V.A.",
                    "last": "Nguyen"
                },
                {
                    "first": "Richard M.",
                    "initial": "R.M.",
                    "last": "Anthony"
                },
                {
                    "first": "Anne Laure",
                    "initial": "A.L.",
                    "last": "Ba\u00f1uls"
                },
                {
                    "first": "Dinh Hoa",
                    "initial": "D.H.",
                    "last": "Vu"
                },
                {
                    "first": "Jan Willem C.",
                    "initial": "J.W.C.",
                    "last": "Alffenaar"
                }
            ],
            "doi": "10.1093/cid/cix992",
            "firstpage": "1625",
            "issn": "10584838",
            "lastpage": "1630",
            "pmid": "29126225",
            "pub_year": 2018,
            "title": "Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention",
            "volume": "66"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Pere Joan",
                    "initial": "P.J.",
                    "last": "Cardona"
                }
            ],
            "doi": "10.3389/fmicb.2016.01536",
            "issn": "1664302X",
            "pub_year": 2016,
            "title": "The progress of therapeutic vaccination with regard to tuberculosis",
            "volume": "7"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Lewis K.",
                    "initial": "L.K.",
                    "last": "Schrager"
                },
                {
                    "first": "Padmapriyadarsini",
                    "initial": "P.",
                    "last": "Chandrasekaran"
                },
                {
                    "first": "Bernard H.",
                    "initial": "B.H.",
                    "last": "Fritzell"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Hatherill"
                },
                {
                    "first": "Paul Henri",
                    "initial": "P.H.",
                    "last": "Lambert"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "McShane"
                },
                {
                    "first": "Nadia",
                    "initial": "N.",
                    "last": "Tornieporth"
                },
                {
                    "first": "Johan",
                    "initial": "J.",
                    "last": "Vekemans"
                }
            ],
            "doi": "10.1016/S1473-3099(18)30421-3",
            "firstpage": "828",
            "issn": "14733099",
            "lastpage": "829",
            "pmid": "30064668",
            "pub_year": 2018,
            "title": "WHO preferred product characteristics for new vaccines against tuberculosis",
            "volume": "18"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Perciaccante"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Coralli"
                },
                {
                    "first": "Otto",
                    "initial": "O.",
                    "last": "Appenzeller"
                }
            ],
            "firstpage": "280",
            "issn": "11249390",
            "lastpage": "282",
            "pmid": "30246774",
            "pub_year": 2018,
            "title": "Amedeo Modigliani and his \u201cgreat secret\u201d: A brief history of medical and social aspects of tuberculosis in the nineteenth and early twentieth century",
            "volume": "26"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Thomas M.",
                    "initial": "T.M.",
                    "last": "Daniel"
                }
            ],
            "doi": "10.1016/j.rmed.2006.08.006",
            "firstpage": "1862",
            "issn": "09546111",
            "lastpage": "1870",
            "pmid": "16949809",
            "pub_year": 2006,
            "title": "The history of tuberculosis",
            "volume": "100"
        },
        "b0115": null,
        "b0120": null,
        "b0125": {
            "authors": [
                {
                    "first": "Margaret J.",
                    "initial": "M.J.",
                    "last": "Grose"
                }
            ],
            "doi": "10.1016/j.healthplace.2010.08.018",
            "firstpage": "94",
            "issn": "13538292",
            "lastpage": "102",
            "pmid": "20851034",
            "pub_year": 2011,
            "title": "Landscape and children's health: Old natures and new challenges for the preventorium",
            "volume": "17"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Wallstedt"
                },
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Maeurer"
                }
            ],
            "doi": "10.1016/j.ijid.2015.01.018",
            "firstpage": "179",
            "issn": "12019712",
            "lastpage": "182",
            "pmid": "25809777",
            "pub_year": 2015,
            "title": "The History of Tuberculosis Management in Sweden",
            "volume": "32"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Rhea N.",
                    "initial": "R.N.",
                    "last": "Coler"
                },
                {
                    "first": "Sylvie",
                    "initial": "S.",
                    "last": "Bertholet"
                },
                {
                    "first": "Samuel O.",
                    "initial": "S.O.",
                    "last": "Pine"
                },
                {
                    "first": "Mark T.",
                    "initial": "M.T.",
                    "last": "Orr"
                },
                {
                    "first": "Valerie",
                    "initial": "V.",
                    "last": "Reese"
                },
                {
                    "first": "Hillarie Plessner",
                    "initial": "H.P.",
                    "last": "Windish"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Davis"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Kahn"
                },
                {
                    "first": "Susan L.",
                    "initial": "S.L.",
                    "last": "Baldwin"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                }
            ],
            "doi": "10.1093/infdis/jis425",
            "firstpage": "1242",
            "issn": "00221899",
            "lastpage": "1252",
            "pmid": "22891286",
            "pub_year": 2013,
            "title": "Therapeutic immunization against mycobacterium tuberculosis is an effective adjunct to antibiotic treatment",
            "volume": "207"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Mamta",
                    "initial": "M.",
                    "last": "Chahar"
                },
                {
                    "first": "Krishan Dutta",
                    "initial": "K.D.",
                    "last": "Rawat"
                },
                {
                    "first": "P. V.J.",
                    "initial": "P.V.J.",
                    "last": "Reddy"
                },
                {
                    "first": "Umesh Dutt",
                    "initial": "U.D.",
                    "last": "Gupta"
                },
                {
                    "first": "Mohan",
                    "initial": "M.",
                    "last": "Natrajan"
                },
                {
                    "first": "Devendra Singh",
                    "initial": "D.S.",
                    "last": "Chauhan"
                },
                {
                    "first": "Kiran",
                    "initial": "K.",
                    "last": "Katoch"
                },
                {
                    "first": "Godavarthi B.K.S.",
                    "initial": "G.B.K.S.",
                    "last": "Prasad"
                },
                {
                    "first": "Vishwa Mohan",
                    "initial": "V.M.",
                    "last": "Katoch"
                }
            ],
            "doi": "10.1016/j.ijtb.2018.08.004",
            "firstpage": "335",
            "issn": "00195707",
            "lastpage": "344",
            "pmid": "30522622",
            "pub_year": 2018,
            "title": "Potential of adjunctive Mycobacterium w (MIP) immunotherapy in reducing the duration of standard chemotherapy against tuberculosis",
            "volume": "65"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Claus",
                    "initial": "C.",
                    "last": "Aagaard"
                },
                {
                    "first": "Truc",
                    "initial": "T.",
                    "last": "Hoang"
                },
                {
                    "first": "Jes",
                    "initial": "J.",
                    "last": "Dietrich"
                },
                {
                    "first": "Pere Joan",
                    "initial": "P.J.",
                    "last": "Cardona"
                },
                {
                    "first": "Angelo",
                    "initial": "A.",
                    "last": "Izzo"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Dolganov"
                },
                {
                    "first": "Gary K.",
                    "initial": "G.K.",
                    "last": "Schoolnik"
                },
                {
                    "first": "Joseph P.",
                    "initial": "J.P.",
                    "last": "Cassidy"
                },
                {
                    "first": "Rolf",
                    "initial": "R.",
                    "last": "Billeskov"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Andersen"
                }
            ],
            "doi": "10.1038/nm.2285",
            "firstpage": "189",
            "issn": "10788956",
            "lastpage": "195",
            "pmid": "21258338",
            "pub_year": 2011,
            "title": "A multistage tuberculosis vaccine that confers efficient protection before and after exposure",
            "volume": "17"
        },
        "b0150": {
            "authors": [
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Van Der Meeren"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Hatherill"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Nduba"
                },
                {
                    "first": "R. J.",
                    "initial": "R.J.",
                    "last": "Wilkinson"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Muyoyeta"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Van Brakel"
                },
                {
                    "first": "H. M.",
                    "initial": "H.M.",
                    "last": "Ayles"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Henostroza"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Thienemann"
                },
                {
                    "first": "T. J.",
                    "initial": "T.J.",
                    "last": "Scriba"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Diacon"
                },
                {
                    "first": "G. L.",
                    "initial": "G.L.",
                    "last": "Blatner"
                },
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "Demoitie"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Tameris"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Malahleha"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Innes"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Hellstrom"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Martinson"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Singh"
                },
                {
                    "first": "E. J.",
                    "initial": "E.J.",
                    "last": "Akite"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Khatoon Azam"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Bollaerts"
                },
                {
                    "first": "A. M.",
                    "initial": "A.M.",
                    "last": "Ginsberg"
                },
                {
                    "first": "T. G.",
                    "initial": "T.G.",
                    "last": "Evans"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Gillard"
                },
                {
                    "first": "D. R.",
                    "initial": "D.R.",
                    "last": "Tait"
                }
            ],
            "doi": "10.1056/NEJMoa1803484",
            "firstpage": "1621",
            "issn": "00284793",
            "lastpage": "1634",
            "pmid": "30280651",
            "pub_year": 2018,
            "title": "Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis",
            "volume": "379"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Xiao Yan",
                    "initial": "X.Y.",
                    "last": "Yang"
                },
                {
                    "first": "Qun Fei",
                    "initial": "Q.F.",
                    "last": "Chen"
                },
                {
                    "first": "You Ping",
                    "initial": "Y.P.",
                    "last": "Li"
                },
                {
                    "first": "Si Miao",
                    "initial": "S.M.",
                    "last": "Wu"
                }
            ],
            "doi": "10.1371/journal.pone.0023826",
            "issn": "19326203",
            "pmid": "21909406",
            "pub_year": 2011,
            "title": "Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: A meta-analysis",
            "volume": "6"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Chen Yi",
                    "initial": "C.Y.",
                    "last": "Huang"
                },
                {
                    "first": "Wen Yeh",
                    "initial": "W.Y.",
                    "last": "Hsieh"
                }
            ],
            "doi": "10.1080/21645515.2017.1335374",
            "firstpage": "1960",
            "issn": "21645515",
            "lastpage": "1971",
            "pmid": "28604170",
            "pub_year": 2017,
            "title": "Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis",
            "volume": "13"
        },
        "b0165": null,
        "b0170": {
            "authors": [
                {
                    "first": "Salla A.",
                    "initial": "S.A.",
                    "last": "Munro"
                },
                {
                    "first": "Simon A.",
                    "initial": "S.A.",
                    "last": "Lewin"
                },
                {
                    "first": "Helen J.",
                    "initial": "H.J.",
                    "last": "Smith"
                },
                {
                    "first": "Mark E.",
                    "initial": "M.E.",
                    "last": "Engel"
                },
                {
                    "first": "Atle",
                    "initial": "A.",
                    "last": "Fretheim"
                },
                {
                    "first": "Jimmy",
                    "initial": "J.",
                    "last": "Volmink"
                }
            ],
            "doi": "10.1371/journal.pmed.0040238",
            "firstpage": "1230",
            "issn": "15491277",
            "lastpage": "1245",
            "pmid": "17676945",
            "pub_year": 2007,
            "title": "Patient adherence to tuberculosis treatment: A systematic review of qualitative research",
            "volume": "4"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Scriba"
                },
                {
                    "first": "Anna K.",
                    "initial": "A.K.",
                    "last": "Coussens"
                },
                {
                    "first": "Helen A.",
                    "initial": "H.A.",
                    "last": "Fletcher"
                }
            ],
            "doi": "10.1128/microbiolspec.TBTB2-0016-2016",
            "issn": "21650497",
            "pmid": "27726784",
            "pub_year": 2017,
            "title": "Human immunology of tuberculosis",
            "volume": "5"
        },
        "b0180": null,
        "b0185": {
            "authors": [
                {
                    "first": "G. A.W.",
                    "initial": "G.A.W.",
                    "last": "Rook"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Al Attiyah"
                }
            ],
            "doi": "10.1016/0041-3879(91)90019-O",
            "firstpage": "13",
            "issn": "00413879",
            "lastpage": "20",
            "pmid": "1882441",
            "pub_year": 1991,
            "title": "Cytokines and the Koch phenomenon",
            "volume": "72"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Ian M.",
                    "initial": "I.M.",
                    "last": "Orme"
                },
                {
                    "first": "Richard T.",
                    "initial": "R.T.",
                    "last": "Robinson"
                },
                {
                    "first": "Andrea M.",
                    "initial": "A.M.",
                    "last": "Cooper"
                }
            ],
            "doi": "10.1038/ni.3048",
            "firstpage": "57",
            "issn": "15292908",
            "lastpage": "63",
            "pmid": "25521685",
            "pub_year": 2015,
            "title": "The balance between protective and pathogenic immune responses in the TB-infected lung",
            "volume": "16"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Angelique Kany Kany",
                    "initial": "A.K.K.",
                    "last": "Luabeya"
                },
                {
                    "first": "Benjamin M.N.",
                    "initial": "B.M.N.",
                    "last": "Kagina"
                },
                {
                    "first": "Michele D.",
                    "initial": "M.D.",
                    "last": "Tameris"
                },
                {
                    "first": "Hennie",
                    "initial": "H.",
                    "last": "Geldenhuys"
                },
                {
                    "first": "Soren T.",
                    "initial": "S.T.",
                    "last": "Hoff"
                },
                {
                    "first": "Zhongkai",
                    "initial": "Z.",
                    "last": "Shi"
                },
                {
                    "first": "Ingrid",
                    "initial": "I.",
                    "last": "Kromann"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Hatherill"
                },
                {
                    "first": "Hassan",
                    "initial": "H.",
                    "last": "Mahomed"
                },
                {
                    "first": "Willem A.",
                    "initial": "W.A.",
                    "last": "Hanekom"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Andersen"
                },
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Scriba"
                },
                {
                    "first": "Elisma",
                    "initial": "E.",
                    "last": "Schoeman"
                },
                {
                    "first": "Colleen",
                    "initial": "C.",
                    "last": "Krohn"
                },
                {
                    "first": "Cheryl L.",
                    "initial": "C.L.",
                    "last": "Day"
                },
                {
                    "first": "Hadn",
                    "initial": "H.",
                    "last": "Africa"
                },
                {
                    "first": "Lebohang",
                    "initial": "L.",
                    "last": "Makhethe"
                },
                {
                    "first": "Erica",
                    "initial": "E.",
                    "last": "Smit"
                },
                {
                    "first": "Yolande",
                    "initial": "Y.",
                    "last": "Brown"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Suliman"
                },
                {
                    "first": "E. Jane",
                    "initial": "E.J.",
                    "last": "Hughes"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Bang"
                },
                {
                    "first": "Margaret A.",
                    "initial": "M.A.",
                    "last": "Snowden"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "McClain"
                },
                {
                    "first": "Gregory D.",
                    "initial": "G.D.",
                    "last": "Hussey"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2015.06.051",
            "firstpage": "4130",
            "issn": "0264410X",
            "lastpage": "4140",
            "pmid": "26095509",
            "pub_year": 2015,
            "title": "First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults",
            "volume": "33"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Andre S.",
                    "initial": "A.S.",
                    "last": "Nell"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "D'Lom"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Bouic"
                },
                {
                    "first": "Montserrat",
                    "initial": "M.",
                    "last": "Sabat\u00e9"
                },
                {
                    "first": "Ramon",
                    "initial": "R.",
                    "last": "Bosser"
                },
                {
                    "first": "Jordi",
                    "initial": "J.",
                    "last": "Picas"
                },
                {
                    "first": "Merc\u00e8",
                    "initial": "M.",
                    "last": "Amat"
                },
                {
                    "first": "Gavin",
                    "initial": "G.",
                    "last": "Churchyard"
                },
                {
                    "first": "Pere Joan",
                    "initial": "P.J.",
                    "last": "Cardona"
                }
            ],
            "doi": "10.1371/journal.pone.0089612",
            "issn": "19326203",
            "pmid": "24586912",
            "pub_year": 2014,
            "title": "Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: Randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection",
            "volume": "9"
        },
        "b0205": {
            "authors": [
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Gillard"
                },
                {
                    "first": "Pan Chyr",
                    "initial": "P.C.",
                    "last": "Yang"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Danilovits"
                },
                {
                    "first": "Wei Juin",
                    "initial": "W.J.",
                    "last": "Su"
                },
                {
                    "first": "Shih Lung",
                    "initial": "S.L.",
                    "last": "Cheng"
                },
                {
                    "first": "Lea",
                    "initial": "L.",
                    "last": "Pehme"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Bollaerts"
                },
                {
                    "first": "Erik",
                    "initial": "E.",
                    "last": "Jongert"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Moris"
                },
                {
                    "first": "Opokua",
                    "initial": "O.",
                    "last": "Ofori-Anyinam"
                },
                {
                    "first": "Marie Ange",
                    "initial": "M.A.",
                    "last": "Demoiti\u00e9"
                },
                {
                    "first": "Marcela",
                    "initial": "M.",
                    "last": "Castro"
                }
            ],
            "doi": "10.1016/j.tube.2016.07.005",
            "firstpage": "118",
            "issn": "14729792",
            "lastpage": "127",
            "pmid": "27553419",
            "pub_year": 2016,
            "title": "Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study",
            "volume": "100"
        },
        "b0210": null
    },
    "body_text": [
        {
            "endOffset": 29265,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "Administering a therapeutic vaccine at the end of standard treatment would not provide an opportunity to study the vaccine effect on cure rates or options to simplify and/or shorten drug treatment regimens but could constitute a first step for establishing proof-of-concept of beneficial vaccine activity before investigating the effects of vaccine administration at an earlier time-point in the treatment course.",
            "startOffset": 28852,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 23567,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Whether such an immune response can be stimulated in persons already receiving drug treatment against the background of active TB, and, if so, whether it contributes to the effectiveness of the drug regimen, remains to be explored.",
            "startOffset": 23336,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 19186,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Cure: For drug-sensitive cases - a pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who is smear-negative or culture-negative at the last month of treatment and on at least one previous occasion.",
            "startOffset": 18953,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 23959,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0155": {
                    "endOffset": 23856,
                    "startOffset": 23849
                },
                "b0160": {
                    "endOffset": 23856,
                    "startOffset": 23849
                }
            },
            "secId": "s0025",
            "sentence": "Additionally, a meta-analysis of data from more than 40 studies assessing the ability of Vaccae\u2122, derived from Mycobacterium vaccae and licensed in China as an immunotherapeutic adjunct to drug treatment of TB in adults, suggested the potential therapeutic utility of this vaccine [31,32] although the strength of evidence, based on data currently available in the public domain, is limited.",
            "startOffset": 23568,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 15918,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Due to the slow rate of replication of Mtb and the difficulty that some of the drugs have in reaching and maintaining therapeutic concentrations within tissue affected by active TB, multiple drugs, over several months, are recommended for treatment of TB, based on a careful analysis of the balance between efficacy and the burden associated with treatment length, complexity and toxicity.",
            "startOffset": 15529,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 37631,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Initial demonstration of preventive vaccine efficacy in other target populations should trigger evaluation of the vaccine as a potential therapeutic adjunct, as these various indications are of importance to public health.",
            "startOffset": 37409,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 29916,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "This relatively early point of immunization may provide an opportunity for the immune response engendered by the vaccine to act in concert with drug treatment to control or kill remaining live Mtb organisms and offer the potential to increase cure rates in addition to reduce rates of recurrence.",
            "startOffset": 29620,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 25559,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "Prevention of long-term pulmonary disability is also an important patient-centered goal.",
            "startOffset": 25471,
            "title": "Public health goals"
        },
        {
            "endOffset": 28282,
            "parents": [],
            "secId": "s0045",
            "sentence": "Such an investment may be more responsible after proof-of-concept is established in individuals with drug-sensitive TB.",
            "startOffset": 28163,
            "title": "Clinical development strategy"
        },
        {
            "endOffset": 34495,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0060",
            "sentence": "A careful safety risk management plan should be instituted to identify and mitigate potential risks.",
            "startOffset": 34395,
            "title": "Safety considerations"
        },
        {
            "endOffset": 25834,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "refoffsets": {
                "b0170": {
                    "endOffset": 25833,
                    "startOffset": 25829
                }
            },
            "secId": "s0035",
            "sentence": "The many months required for treating drug-sensitive TB and furthermore MDR-TB and XDR-TB frequently result in poor patient compliance with necessary drug regimens [34].",
            "startOffset": 25665,
            "title": "Public health goals"
        },
        {
            "endOffset": 36875,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Mtb samples obtained prior to the initiation of treatment should be available to assess whether a given recurrence is due to reactivation of the same, initially infecting Mtb strain, or whether it results from a de novo, Mtb infection that occurred near or post end-of-treatment.",
            "startOffset": 36596,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 30273,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "A third possible time for administering a therapeutic vaccine would be at or around the time of TB diagnosis or initiation of treatment.",
            "startOffset": 30137,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 34072,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0060",
            "sentence": "Respiratory function tests may be useful to monitor lung safety and measure therapeutic impact on lung morbidity.",
            "startOffset": 33959,
            "title": "Safety considerations"
        },
        {
            "endOffset": 30459,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "refoffsets": {
                "b0175": {
                    "endOffset": 30458,
                    "startOffset": 30454
                }
            },
            "secId": "s0050",
            "sentence": "However, vaccine responses administered at this time of maximal mycobacterial load have the potential to be affected by the profound impact of active TB disease on innate immunity [35].",
            "startOffset": 30274,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 23167,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 23166,
                    "startOffset": 23162
                }
            },
            "secId": "s0025",
            "sentence": "Vaccination of Mtb infected individuals: Primary results from a phase 2B clinical trial assessing the effect of 2 doses of the M72/AS01E candidate TB vaccine on rates of progression to TB disease in individuals with LTBI demonstrated 54% efficacy at 2.3 years following vaccination for the primary endpoint of bacteriologically confirmed active pulmonary TB (95% CI, 2.9 to 78.2; P = 0.04) [30].",
            "startOffset": 22772,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 31929,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "Participants should have access to local delivery of care in a routine setting according to national and WHO recommendations, with local ethics committee oversight.",
            "startOffset": 31765,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 14142,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 14141,
                    "startOffset": 14138
                }
            },
            "secId": "s0010",
            "sentence": "Approximately 1.7 billion people \u2013 23% of the world\u2019s population \u2013 harbour latent TB infection (LTBI) [2].",
            "startOffset": 14036,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 14324,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0015": {
                    "endOffset": 14323,
                    "startOffset": 14320
                }
            },
            "secId": "s0010",
            "sentence": "Approximately 5% develop active TB in the first 18 months after initial infection while an additional 5% would be expected to develop TB over the remaining years of their lives [3].",
            "startOffset": 14143,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 15336,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 15335,
                    "startOffset": 15332
                }
            },
            "secId": "s0015",
            "sentence": "The first use of streptomycin against TB in 1944, and subsequent development of multiple other compounds, provided hope for patients [5].",
            "startOffset": 15199,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 18045,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 18044,
                    "startOffset": 18037
                },
                "b0080": {
                    "endOffset": 18044,
                    "startOffset": 18037
                },
                "b0085": {
                    "endOffset": 18044,
                    "startOffset": 18037
                },
                "b0090": {
                    "endOffset": 18044,
                    "startOffset": 18037
                }
            },
            "secId": "s0015",
            "sentence": "New strategies in treating drug-resistant TB, utilizing drug combinations that include more recent TB drugs such as bedaquiline, delamanid, and linezolid offer the hope for better treatment of drug-resistant TB, but strains resistant to each of these new drugs have already been identified, sounding a note of caution against reliance on drug therapy to cure drug-resistant TB well into the future [15\u201318].",
            "startOffset": 17639,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 26508,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "Shortening and/or simplifying treatment regimens is considered an essential public health goal, but, in the absence of reliable animal or early clinical models for therapeutic vaccines and in order to manage risk in study participants, proof-of-principle for therapeutic vaccine efficacy should first be established in study participants receiving standard of care drug regimens, before attempts are made to shorten or simplify new drug regimens in combination with vaccination.",
            "startOffset": 26030,
            "title": "Public health goals"
        },
        {
            "endOffset": 26735,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0040",
            "sentence": "Ultimately, the target population for therapeutic TB vaccines is all persons, regardless of age, during or towards the end of treatment for active TB disease, due to drug-sensitive or drug-resistant strains.",
            "startOffset": 26528,
            "title": "Target population"
        },
        {
            "endOffset": 27654,
            "parents": [],
            "secId": "s0045",
            "sentence": "When proof-of-concept is established, when appropriate, effectiveness in special population groups should also be evaluated (e.g., HIV infection, diabetes, pregnant women, the elderly, young children), as no-one should be excluded from potentially benefitting from this intervention, if proven safe and effective.",
            "startOffset": 27341,
            "title": "Clinical development strategy"
        },
        {
            "endOffset": 21012,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 21011,
                    "startOffset": 21007
                }
            },
            "secId": "s0020",
            "sentence": "The World Health Organization (WHO) Preferred Product Characteristics for vaccines aimed at preventing primary pulmonary TB disease in subjects with and without LTBI have been described elsewhere [20].",
            "startOffset": 20811,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 30547,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "Also, symptoms associated to TB may obscure the ability to characterize vaccine safety.",
            "startOffset": 30460,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 32094,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "Access to care should include basic radiological and microbiological services to ensure that Mtb microbiological samples can be stored and locally or remotely typed.",
            "startOffset": 31929,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 37155,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Investigations in special populations should be initiated rapidly after initial demonstration of efficacy.",
            "startOffset": 37049,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 19469,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Treatment failure refers to a case where cure is not achieved.",
            "startOffset": 19407,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 30137,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "Eventually, in a secondary step, vaccination at this time point also would provide the opportunity to investigate the potential for a therapeutic vaccine to reduce the duration and number of drugs required for treatment.",
            "startOffset": 29917,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 16173,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "The recommended first line regimen for treating drug-sensitive pulmonary TB comprises an intensive phase of 2 months of isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) followed by a continuation phase of 4 months of INH and RIF.",
            "startOffset": 15919,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 36273,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Achieving proof-of-concept for a therapeutic vaccine based on the ability of the vaccine to reduce recurrence rates over one year or more following a drug-mediated cure represents the preferred short-term strategic goal of therapeutic TB vaccine development.",
            "startOffset": 36015,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 29482,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "If multiple vaccine doses are required, the question of compliance with immunization schedule will require careful consideration, and it may be desirable to plan for all doses to be delivered before end of treatment.",
            "startOffset": 29266,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 14579,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "230,000 deaths were due to drug-resistant TB.",
            "startOffset": 14534,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 13982,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 13981,
                    "startOffset": 13978
                }
            },
            "secId": "s0010",
            "sentence": "TB is the leading cause of death globally from a single infectious agent, Mycobacterium tuberculosis (Mtb), having killed approximately 1.6 million persons in 2017, including approximately 300,000 HIV-infected people [2].",
            "startOffset": 13761,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 35981,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0065",
            "sentence": "Some aspects of a potentially effective therapeutic vaccine may diverge from those proposed in this PPC, which would not necessarily preclude successful licensure and policy decision for clinical application.",
            "startOffset": 35773,
            "title": "The PPC for a therapeutic vaccine for TB (Table 2)"
        },
        {
            "endOffset": 35033,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0065",
            "sentence": "The primary audience for this WHO PPC document includes all entities involved in the development of therapeutic vaccines for improvement of TB treatment outcomes.",
            "startOffset": 34871,
            "title": "The PPC for a therapeutic vaccine for TB (Table 2)"
        },
        {
            "endOffset": 17467,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 17466,
                    "startOffset": 17462
                }
            },
            "secId": "s0015",
            "sentence": "Individual patient risks for recurrence include suboptimal adherence to the initial drug regimen, initial bacillary load [12].",
            "startOffset": 17341,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 21917,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 21916,
                    "startOffset": 21909
                },
                "b0125": {
                    "endOffset": 21916,
                    "startOffset": 21909
                },
                "b0130": {
                    "endOffset": 21916,
                    "startOffset": 21909
                }
            },
            "secId": "s0025",
            "sentence": "Effective immunity resulting from natural exposure: Following natural Mtb exposure, an estimated 90% of individuals do not progress to active disease, showing evidence of host capacity to limit TB progression [24\u201326].",
            "startOffset": 21700,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 24461,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "Reducing the rate of recurrence following completion of a full course of drug therapy.",
            "startOffset": 24375,
            "title": "Public health goals"
        },
        {
            "endOffset": 32251,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "For vaccines administered during drug treatment, monitoring of sputum clearance and relapse should be planned at various moments including end-of-treatment.",
            "startOffset": 32095,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 18336,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Panel.",
            "startOffset": 18330,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 19826,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Recurrence may include cases of reactivation of the incompletely eradicated Mtb strain responsible for the initial episode of TB (here referred to as relapse), and cases of re-infection with a new Mtb strain.",
            "startOffset": 19618,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 24373,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "Public health goals for therapeutic vaccines include reducing the rate of recurrence following completion of a full course of drug therapy; increasing the proportion of patients cured; shortening the necessary treatment duration and reducing the number of drugs to achieve a cure, all both for TB caused by drug-sensitive and drug-resistant Mtb strains.",
            "startOffset": 24020,
            "title": "Public health goals"
        },
        {
            "endOffset": 17639,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 17638,
                    "startOffset": 17631
                },
                "b0060": {
                    "endOffset": 17638,
                    "startOffset": 17631
                },
                "b0065": {
                    "endOffset": 17638,
                    "startOffset": 17631
                },
                "b0070": {
                    "endOffset": 17638,
                    "startOffset": 17631
                }
            },
            "secId": "s0015",
            "sentence": "Most recurrences occur between 6 months and two years of completing treatment [11\u201314].",
            "startOffset": 17553,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 25191,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "refoffsets": {
                "b0165": {
                    "endOffset": 25190,
                    "startOffset": 25186
                }
            },
            "secId": "s0035",
            "sentence": "Increasing the proportion of patients surviving to cure: this would represent a major advance for public health, particularly in cases of drug-resistant TB given the poor rates of survival and cure when treating MDR-TB and, particularly, XDR-TB [33].",
            "startOffset": 24941,
            "title": "Public health goals"
        },
        {
            "endOffset": 37696,
            "parents": [],
            "secId": "s0075",
            "sentence": "Tuberculosis Vaccine Initiative, Lelystad, The Netherlands",
            "startOffset": 37638,
            "title": "Funding"
        },
        {
            "endOffset": 22771,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Whether these observations are predictive of protection in humans is however unknown.",
            "startOffset": 22686,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 15065,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "If untreated, TB often results in months to years of progressively diminishing productivity, while the cough serves to spread Mtb through the air, putting persons sharing the same home, school, social or work environment at risk of Mtb infection.",
            "startOffset": 14819,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 33146,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "Based on the assumption of an interaction between drug treatment and an immunotherapeutic vaccine effect (illustrated by the fact that a therapeutic vaccine would not be expected to provide a cure on its own, replacing the need for treatment), capacity strengthening efforts leading to increased access and delivery of care may affect the generalizability to real life settings of the effect of therapeutic vaccines as measured in a trial.",
            "startOffset": 32707,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 35772,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0065",
            "sentence": "The PPC criteria proposed are aspirational in nature.",
            "startOffset": 35719,
            "title": "The PPC for a therapeutic vaccine for TB (Table 2)"
        },
        {
            "endOffset": 33766,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "refoffsets": {
                "b0185": {
                    "endOffset": 33645,
                    "startOffset": 33641
                }
            },
            "secId": "s0060",
            "sentence": "The potential for the injection of antigenic components of Mtb precipitating a delayed-type (Type IV) hypersensitivity reaction, resulting in necrosis at the site of injection, in persons with Mtb infection or active TB [37] represents a possibility that must be considered when testing therapeutic TB vaccines on persons with active TB disease.",
            "startOffset": 33421,
            "title": "Safety considerations"
        },
        {
            "endOffset": 33958,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "refoffsets": {
                "b0190": {
                    "endOffset": 33836,
                    "startOffset": 33832
                }
            },
            "secId": "s0060",
            "sentence": "The possibility of pulmonary and systemic inflammatory reactions [38] , and the breakdown of granuloma structure potentially resulting in Mtb dissemination should be considered and monitored.",
            "startOffset": 33767,
            "title": "Safety considerations"
        },
        {
            "endOffset": 17552,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 17551,
                    "startOffset": 17546
                },
                "b0040": {
                    "endOffset": 17551,
                    "startOffset": 17546
                }
            },
            "secId": "s0015",
            "sentence": "Infection with a drug-resistant strain, smoking, HIV infection, and cavitation [1,8].",
            "startOffset": 17467,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 28423,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "A therapeutic vaccine could be administered to TB patients around the time of completion of drug treatment.",
            "startOffset": 28316,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 21461,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 21460,
                    "startOffset": 21456
                }
            },
            "secId": "s0020",
            "sentence": "Several vaccine candidates are presently considered for use as therapeutic TB vaccines, including attenuated and inactivated-whole organisms, fragmented mycobacteria and adjuvanted protein subunit molecules [23].",
            "startOffset": 21249,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 37408,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Proof-of-concept should imperatively trigger vaccine evaluation for other indications including prevention of TB in the general population or in recently exposed individuals.",
            "startOffset": 37234,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 19407,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "For drug-resistant cases - treatment completed as recommended by the national policy without evidence of failure AND three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase.",
            "startOffset": 19187,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 32408,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "For vaccines administered towards the end-of-treatment, active or passive monitoring of recurrence should be planned, over at least one year post treatment.",
            "startOffset": 32252,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 28548,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "Assessing the efficacy of a vaccine administered at this time necessarily would focus on reducing the rate of TB recurrence.",
            "startOffset": 28424,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 30958,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "Whatever the timing of therapeutic vaccination, it will be important to prospectively obtain and bank mycobacterial specimens prior to the onset of initial drug treatment to support strain characterization in the context of outcome monitoring.",
            "startOffset": 30715,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 14818,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0015": {
                    "endOffset": 14817,
                    "startOffset": 14814
                }
            },
            "secId": "s0015",
            "sentence": "Active TB is most commonly a disease of the lungs, but can be extra-pulmonary and disseminated [3].",
            "startOffset": 14719,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 14035,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "An estimated 10 million people developed TB in 2017.",
            "startOffset": 13983,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 18330,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Given the challenges inherent in drug treatment of TB, developing vaccine strategies with the potential to improve outcomes of drug treatment regimens for persons with TB caused by either drug-sensitive or drug-resistant strains represents an important global public health imperative.",
            "startOffset": 18045,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 16663,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 16662,
                    "startOffset": 16659
                }
            },
            "secId": "s0015",
            "sentence": "The toxicity of the drugs included in the regimens can be devastating, with potential hearing loss, nephrotoxicity, skin rashes and neurological disorders [7].",
            "startOffset": 16504,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 21248,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 21247,
                    "startOffset": 21240
                },
                "b0110": {
                    "endOffset": 21247,
                    "startOffset": 21240
                }
            },
            "secId": "s0020",
            "sentence": "The potential for therapeutic vaccine strategies to improve TB treatment outcomes has been recognized since the time of Robert Koch and his attempt to use tuberculin to treat disease, prior to the advent of antibiotic treatment [21,22].",
            "startOffset": 21012,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 29619,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "Another potential time for therapeutic vaccine administration is around the conclusion of the initial, intensive phase of drug treatment.",
            "startOffset": 29482,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 16752,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 16751,
                    "startOffset": 16746
                },
                "b0040": {
                    "endOffset": 16751,
                    "startOffset": 16746
                }
            },
            "secId": "s0015",
            "sentence": "Additionally, the costs of treating patients with MDR-TB and XDR-TB are very high [2,8].",
            "startOffset": 16664,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 27340,
            "parents": [],
            "secId": "s0045",
            "sentence": "To reduce background heterogeneity, maximize safety and efficacy data interpretability and manage risk exposure in a vulnerable, sick population, proof-of-concept testing may be best done in adults with TB and without comorbidities known either to reduce the likelihood of curing their TB disease or diminish the potential effectiveness of a vaccine.",
            "startOffset": 26990,
            "title": "Clinical development strategy"
        },
        {
            "endOffset": 34394,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 34187,
                    "startOffset": 34174
                },
                "b0150": {
                    "endOffset": 34187,
                    "startOffset": 34174
                },
                "b0195": {
                    "endOffset": 34187,
                    "startOffset": 34174
                },
                "b0200": {
                    "endOffset": 34187,
                    "startOffset": 34174
                },
                "b0205": {
                    "endOffset": 34393,
                    "startOffset": 34389
                }
            },
            "secId": "s0060",
            "sentence": "Mostly minor adverse events have been observed in most therapeutic vaccine studies conducted to date [19,30,39,40], but enrollment in a phase 2 trial of the M72/AS01E vaccine candidate was interrupted prematurely after the observation in TB patients of local reactions (pain, redness, swelling) larger than expected [41].",
            "startOffset": 34073,
            "title": "Safety considerations"
        },
        {
            "endOffset": 15528,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 15527,
                    "startOffset": 15524
                }
            },
            "secId": "s0015",
            "sentence": "Even in cured patients, there can be pulmonary sequelae and respiratory disability [6].",
            "startOffset": 15441,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 34818,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0060",
            "sentence": "The potential severity of TB, compared to healthy people at minimal risk of health outcomes, may justify considering different acceptable safety thresholds for therapeutic vaccines than for prophylactic vaccines.",
            "startOffset": 34606,
            "title": "Safety considerations"
        },
        {
            "endOffset": 28162,
            "parents": [],
            "secId": "s0045",
            "sentence": "Additionally, enrolling a cohort of persons with drug-resistant TB into large-scale clinical efficacy trials is likely to prove difficult, requiring multiple sites and high costs.",
            "startOffset": 27983,
            "title": "Clinical development strategy"
        },
        {
            "endOffset": 28851,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "This may correspond to a time at which the load of viable bacteria potentially able to cause relapse may be minimal, and immune functions restored following a time of suppression associated with overt disease and bacterial replication, altogether allowing for a most effective immune effector response.",
            "startOffset": 28549,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 25664,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "Shortening the duration of drug treatment and/or reducing the number of drugs necessary to affect cure.",
            "startOffset": 25561,
            "title": "Public health goals"
        },
        {
            "endOffset": 15440,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Despite the availability of antimycobacterial drugs, treating TB remains a long and difficult endeavor.",
            "startOffset": 15337,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 37233,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Shortening and simplifying drug regimens represent essential long-term goals.",
            "startOffset": 37156,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 22594,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Observed changes that may have contributed include a reduced number of myeloid-derived suppressor cells in the lung, an increased number of natural killer T-cells, CD4 T cell activation and TNF-\u03b1 release.",
            "startOffset": 22390,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 24626,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "This goal, often referred to as prevention of recurrent disease (PoR), which may result from relapse or re-infection, represents an important public health outcome.",
            "startOffset": 24462,
            "title": "Public health goals"
        },
        {
            "endOffset": 26800,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0040",
            "sentence": "The medical need for a therapeutic vaccine against TB is global.",
            "startOffset": 26736,
            "title": "Target population"
        },
        {
            "endOffset": 22389,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 22388,
                    "startOffset": 22381
                },
                "b0140": {
                    "endOffset": 22388,
                    "startOffset": 22381
                }
            },
            "secId": "s0025",
            "sentence": "Animal models support the therapeutic vaccination strategy: Studies of therapeutic vaccination in animal TB models indicate potential for improved drug treatment outcomes [27,28].",
            "startOffset": 22210,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 36595,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Initial studies should be conducted in the context of standard recommended drug treatment.",
            "startOffset": 36505,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 17049,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Adverse outcomes considered here include treatment failure and recurrences (see Panel for outcome definitions).",
            "startOffset": 16938,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 14437,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "The transmission of TB caused by Mtb strains resistant to TB drugs represents a growing threat to public health.",
            "startOffset": 14325,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 14533,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0010",
            "sentence": "An estimated 558,000 people developed drug-resistant TB in 2017, 82% being multidrug-resistant.",
            "startOffset": 14438,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 23335,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "These results show that this vaccine generates an immune response capable of preventing LTBI or new infections from developing into overt, active pulmonary TB disease.",
            "startOffset": 23168,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 16937,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 16936,
                    "startOffset": 16933
                }
            },
            "secId": "s0015",
            "sentence": "Globally, an estimated 85% of cases of drug-sensitive TB, and only 55% of cases of drug-resistant TB and 30% of XDR-TB, are successfully cured at the end of the initiated treatment [2].",
            "startOffset": 16752,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 20187,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "This contrasts with prophylactic vaccines aimed to prevent disease in the first place, in this case TB.",
            "startOffset": 20084,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 20810,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "This is an important vaccine target indication when considering the need to protect exposed contacts, some of whom can be identified as recent converters by diagnostic tests for LTBI, but this is not in scope of the present report.",
            "startOffset": 20579,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 21699,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Although the immunological mechanisms of in vivo control and killing of Mtb are poorly understood, several observations argue in favor of the technical feasibility of development of a therapeutic vaccination for TB:",
            "startOffset": 21484,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 35464,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0065",
            "sentence": "It is anticipated that PPCs provide a framework for developers to design their development plan and define in more detail specific target product profiles.",
            "startOffset": 35309,
            "title": "The PPC for a therapeutic vaccine for TB (Table 2)"
        },
        {
            "endOffset": 22685,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 22684,
                    "startOffset": 22680
                }
            },
            "secId": "s0025",
            "sentence": "Favorable results have also been found in animal models of post-exposure vaccination [29].",
            "startOffset": 22595,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 31395,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 31375,
                    "startOffset": 31372
                },
                "b0180": {
                    "endOffset": 31350,
                    "startOffset": 31346
                }
            },
            "secId": "s0055",
            "sentence": "Before confirmation of any therapeutic vaccine efficacy in a proof-of-concept trial, standard TB drug treatment recommendations for drug-sensitive TB [36] or drug-resistant TB [7] should be followed.",
            "startOffset": 31196,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 16503,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 16470,
                    "startOffset": 16467
                }
            },
            "secId": "s0015",
            "sentence": "The emergence and transmission of drug-resistant Mtb strains, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), has further complicated attempts to treat TB disease, requiring a combination of five or more drugs to be administered for nine months or longer [7], sometimes requiring injections.",
            "startOffset": 16174,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 17184,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 17183,
                    "startOffset": 17177
                },
                "b0050": {
                    "endOffset": 17183,
                    "startOffset": 17177
                }
            },
            "secId": "s0015",
            "sentence": "Recurrence can occur either due to reactivation of the incompletely eliminated initial infecting organism, or from reinfection [9,10].",
            "startOffset": 17050,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 25470,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "Increasing cure rates would reduce the number of persons required to receive extended periods of treatment, particularly with second-line and third-line injectable drugs, thereby potentially reducing the risk of serious, debilitating adverse effects associated with these drugs.",
            "startOffset": 25192,
            "title": "Public health goals"
        },
        {
            "endOffset": 34605,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0060",
            "sentence": "Safety data will need to be interpreted in the context of co-administered drug treatment to sick individuals.",
            "startOffset": 34496,
            "title": "Safety considerations"
        },
        {
            "endOffset": 35308,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 35165,
                    "startOffset": 35161
                }
            },
            "secId": "s0065",
            "sentence": "This PPC is presented as a complement to the existing WHO PPC on the development of TB vaccines intended to prevent TB disease [20], providing guidance to scientists, funding agencies, and public and private sector organizations developing therapeutic TB vaccine candidates.",
            "startOffset": 35034,
            "title": "The PPC for a therapeutic vaccine for TB (Table 2)"
        },
        {
            "endOffset": 26960,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0040",
            "sentence": "TB patients otherwise healthy as well as patients with co-morbidities or other risk factors should be allowed to benefit from an intervention proven effective.",
            "startOffset": 26801,
            "title": "Target population"
        },
        {
            "endOffset": 19899,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "These can be diffentiated through molecular Mtb strain characterization.",
            "startOffset": 19827,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 24939,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "In addition to providing benefit for the patient, reducing rates of recurrent disease would also reduce the chance of Mtb transmission to family members, friends and co-workers, medical personnel and the community at large that otherwise could occur if these individuals once again developed active pulmonary TB.",
            "startOffset": 24627,
            "title": "Public health goals"
        },
        {
            "endOffset": 36504,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "Assessing the efficacy of a vaccine delivered at some point during treatment, possibly at the end of the initial intensive treatment phase, against end-treatment failure and recurrence, may also be considered as a short-term goal.",
            "startOffset": 36274,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 13760,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 13759,
                    "startOffset": 13756
                }
            },
            "secId": "s0010",
            "sentence": "Developing interventions against tuberculosis (TB), including new TB vaccines, represents a critical global health priority [1].",
            "startOffset": 13632,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 20578,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "Another but related TB vaccine indication relates to the prevention of progression to TB disease in individuals with LTBI, sometimes referred to as a post-exposure vaccine strategy.",
            "startOffset": 20397,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 31148,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "More specifically, differentiating relapse from re-infection during the post-treatment phase, and identifying de novo emergence of drug-resistant strains, will provide valuable information.",
            "startOffset": 30959,
            "title": "Timing of immunization (Fig. 1)"
        },
        {
            "endOffset": 20083,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0020",
            "sentence": "Therapeutic vaccines are administered to persons who have already manifested signs and symptoms of disease caused by the targeted organism, in this case, Mtb.",
            "startOffset": 19925,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 26029,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Public health Goals, target population"
                }
            ],
            "secId": "s0035",
            "sentence": "Lengthy and complex drug regimens needed to treat drug-resistant Mtb frequently result in drug-related toxicities that also diminish compliance and increase the possibility of treatment failure.",
            "startOffset": 25835,
            "title": "Public health goals"
        },
        {
            "endOffset": 19617,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "Recurrence: In a bacteriologically confirmed case of TB, recurrence refers to reversion to sputum positivity after successful end of treatment cure.",
            "startOffset": 19469,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 22209,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0025",
            "sentence": "Boosting protective host responses through immunization during treatment for active disease could enhance killing of mycobacteria during ongoing drug treatment, thereby reducing the proportion of subjects at risk of relapse due to residual, viable mycobacteria following treatment cessation.",
            "startOffset": 21918,
            "title": "Biologic feasibility"
        },
        {
            "endOffset": 37048,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0070",
            "sentence": "While initial proof-of-concept may best be generated in patients with drug-sensitive TB, reducing the emergence of drug-resistant TB represents an important strategic goal.",
            "startOffset": 36876,
            "title": "Conclusions and strategic goals"
        },
        {
            "endOffset": 18396,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0210": {
                    "endOffset": 18396,
                    "startOffset": 18392
                }
            },
            "secId": "s0015",
            "sentence": "Case definitions, as per available WHO recommendations [42]",
            "startOffset": 18337,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 33397,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "For initial proof-of-concept generation, the administration of vaccines at the end of treatment in individuals enrolled only after end of treatment delivered in a routine setting, may be an appropriate way of mitigating the generalizability question.",
            "startOffset": 33147,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 18646,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "A bacteriologically confirmed case is one from whom a biological specimen is confirmed positive by culture or WHO-approved rapid diagnostic method.",
            "startOffset": 18499,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 35594,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0065",
            "sentence": "WHO PPCs are developed following a consensus-generating wide consultation process involving experts and stakeholders in the field.",
            "startOffset": 35464,
            "title": "The PPC for a therapeutic vaccine for TB (Table 2)"
        },
        {
            "endOffset": 18769,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "MDR-TB is defined as Mtb isolates resistant to the two, first-line treatments for TB: rifampicin (RIF) and isoniazid (INH).",
            "startOffset": 18646,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 15199,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0020": {
                    "endOffset": 15198,
                    "startOffset": 15195
                }
            },
            "secId": "s0015",
            "sentence": "Without treatment, the TB case-fatality rate in HIV-uninfected individuals is approximately 70% within 10 years of disease onset [4].",
            "startOffset": 15066,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 18498,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "A bacteriologically confirmed case of TB is the preferred endpoint for TB vaccine efficacy assessment.",
            "startOffset": 18396,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 27982,
            "parents": [],
            "secId": "s0045",
            "sentence": "Although subjects with drug-resistant TB represent a very important potential target for therapeutic vaccines, the large variation between individuals in disease course and types of resistance is likely to influence treatment outcome, increasing background variability and potentially affecting estimation of the vaccine effect.",
            "startOffset": 27654,
            "title": "Clinical development strategy"
        },
        {
            "endOffset": 31764,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "It would be ethically inappropriate to provide participants with a shortened or simplified treatment regimen before any demonstration of vaccine-induced increased cure rates and/or reduction of relapses, in absence of reliable pre-clinical or early clinical models establishing strong confidence in protective immunotherapeutic effects of a specific vaccine candidate.",
            "startOffset": 31396,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 35718,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0065",
            "sentence": "Key policy considerations are highlighted, but preferred attributes expressed here do not pre-empt future policy decisions.",
            "startOffset": 35595,
            "title": "The PPC for a therapeutic vaccine for TB (Table 2)"
        },
        {
            "endOffset": 17340,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 17339,
                    "startOffset": 17332
                },
                "b0055": {
                    "endOffset": 17339,
                    "startOffset": 17332
                },
                "b0060": {
                    "endOffset": 17339,
                    "startOffset": 17332
                },
                "b0065": {
                    "endOffset": 17339,
                    "startOffset": 17332
                }
            },
            "secId": "s0015",
            "sentence": "Reports of recurrence rates vary, often between 2 and 15%, with higher rates seen in countries demonstrating high TB incidence and poor TB control [10\u201313].",
            "startOffset": 17185,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 18953,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "secId": "s0015",
            "sentence": "XDR-TB defined as Mtb isolates resistant to INH and RIF, as well as any fluoroquinolone and at least one of the three injectable second-line drugs (amikacin, kanamycin or capreomycin).",
            "startOffset": 18769,
            "title": "Drug treatment recommendations and outcomes"
        },
        {
            "endOffset": 14673,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 14672,
                    "startOffset": 14669
                }
            },
            "secId": "s0010",
            "sentence": "Globally, 3.5% of new TB cases and 18% of previously treated cases had drug-resistant TB [2].",
            "startOffset": 14580,
            "title": "Tuberculosis burden"
        },
        {
            "endOffset": 32706,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0055",
            "sentence": "The degree of treatment adherence and quality of treatment administration provided in the context of a trial will assuredly impact cure and recurrence rates and the sample size needed to demonstrate efficacy of a therapeutic vaccine (sample size assumptions and estimates are presented in Table 1).",
            "startOffset": 32408,
            "title": "Standards of care, efficacy and effectiveness"
        },
        {
            "endOffset": 20396,
            "parents": [
                {
                    "id": "s0005",
                    "title": "Introduction"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 20395,
                    "startOffset": 20391
                }
            },
            "secId": "s0020",
            "sentence": "The scope of this report relates to therapeutic vaccination against TB intended to stimulate an individual\u2019s immune response in combination with drug treatment, in an effort to improve treatment outcome [19].",
            "startOffset": 20188,
            "title": "Therapeutic vaccination"
        },
        {
            "endOffset": 30715,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Clinical development strategy"
                }
            ],
            "secId": "s0050",
            "sentence": "Early vaccine administration during treatment may have the potential to influence immune-pathology leading to long term pulmonary disability, which should be evaluated.",
            "startOffset": 30547,
            "title": "Timing of immunization (Fig. 1)"
        }
    ],
    "docId": "S0264410X19314616",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "vekemansj@who.int",
                "first": "Johan",
                "initial": "J.",
                "last": "Vekemans"
            },
            {
                "email": null,
                "first": "Michael James",
                "initial": "M.J.",
                "last": "Brennan"
            },
            {
                "email": null,
                "first": "Mark",
                "initial": "M.",
                "last": "Hatherill"
            },
            {
                "email": null,
                "first": "Lewis",
                "initial": "L.",
                "last": "Schrager"
            },
            {
                "email": null,
                "first": "Bernard",
                "initial": "B.",
                "last": "Fritzell"
            },
            {
                "email": null,
                "first": "Kathryn",
                "initial": "K.",
                "last": "Rutkowski"
            },
            {
                "email": null,
                "first": "Beatrice",
                "initial": "B.",
                "last": "De Vos"
            },
            {
                "email": null,
                "first": "Matteo",
                "initial": "M.",
                "last": "Zignol"
            },
            {
                "email": null,
                "first": "Georges",
                "initial": "G.",
                "last": "Thiry"
            },
            {
                "email": null,
                "first": "Ann M.",
                "initial": "A.M.",
                "last": "Ginsberg"
            },
            {
                "email": null,
                "first": "Barry",
                "initial": "B.",
                "last": "Walker"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.10.072",
        "firstpage": "135",
        "issn": "0264410X",
        "keywords": [
            "Immunotherapeutic",
            "Mycobacterium tuberculosis",
            "Prevention",
            "Relapse",
            "Tuberculosis",
            "Vaccines"
        ],
        "lastpage": "142",
        "openaccess": "Full",
        "pub_year": 2020,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations"
    }
}